Constitutive Protease-activated Receptor-2-mediated Migration of MDA MB-231 Breast Cancer Cells Requires Both β-Arrestin-1 and -2
Population
Metastatic breast cancer cell line (MDA MB-231) and a less metastatic PAR-2 expressing breast cancer cell line
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Identifies PAR-2 pathway as potential target in metastatic breast cancer; Level 5 evidence leaves open clinical translation.
Key Points
- To investigate the mechanism of constitutive PAR-2-mediated motility in metastatic breast cancer cells and evaluate the individual roles of beta-arrestin-1 and beta-arrestin-2.
- Compared constitutive migration, protein localization, and protease secretion between metastatic MDA MB-231 cells and a less metastatic PAR-2-expressing breast cancer cell line.
- Used small interfering RNA (siRNA) to specifically silence beta-arrestin-1 and beta-arrestin-2 expression.
- Treated cells with MEK-1 inhibitors, trypsin inhibitors, and a scrambled PAR-2 peptide to assess signaling dependency.
- MDA MB-231 cells secreted a trypsin-like protease that stimulated autocrine PAR-2 activation, with PAR-2, beta-arrestin-2, and phosphorylated ERK1/2 co-localizing to pseudopodia.
- siRNA-mediated silencing of either beta-arrestin-1 or beta-arrestin-2, as well as treatment with MEK-1 or trypsin inhibitors, reduced baseline migration of MDA MB-231 cells.
- Less metastatic cells showed neither constitutive migration nor trypsin secretion, exhibiting a uniform peripheral distribution of PAR-2 rather than pseudopodial localization.
Structured PICO
P
Population
Metastatic breast cancer cell line (MDA MB-231) and a less metastatic PAR-2 expressing breast cancer cell line
I
Intervention
Small interfering RNA (siRNA) silencing of beta-arrestins, MEK-1 inhibitors, trypsin inhibitors, and a scrambled PAR-2 peptide
O
Outcome
Cell migrationsurrogate
Autocrine activation of PAR-2 by secreted proteases contributes to the migration of metastatic breast cancer cells through beta-arrestin-dependent ERK1/2 activation.
Cite This Study
Ge et al. (2004) studied this question.